PerkinElmer Launches New Live Cell Capabilities for Operetta® High Content Imaging System

  PerkinElmer Launches New Live Cell Capabilities for Operetta® High Content
  Imaging System

  New capabilities provide increased biologically relevant data for improved
                   efficiency in the drug discovery process

Business Wire

WALTHAM, Mass. -- July 24, 2013

PerkinElmer, Inc., a global leader focused on the health and safety of people
and the environment, has announced enhancements for its Operetta^® High
Content Imaging System, designed to significantly improve the ability of
scientists to perform live cell assays with higher throughput, to help foster
a better understanding of normal and aberrant cellular behavior.

The latest version of Operetta's software, Harmony 3.5, enables scientists to
track individual cells ...

The latest version of Operetta's software, Harmony 3.5, enables scientists to
track individual cells over time for a better understanding of dynamic
processes and to generate more accurate prediction models. (Photo: Business
Wire)

Scientists conducting research in the areas of cancer, stem cells or
infectious diseases will benefit from the Operetta system’s new capabilities
to analyze the dynamic behavior of cells using advanced live cell, high
content imaging. With the new capabilities, users will be able to accurately
observe individual cell behavior over time to better understand dynamic
processes in order to generate more accurate prediction models, for example
how cancer cells migrate during metastasis or how viruses invade cells.

“We are seeing a trend towards researchers using biological assays that are
better models of the physiological environment in vivo earlier in the drug
discovery process in order to improve the likelihood of a drug succeeding at
clinical trial.” said Jim Corbett, President, Diagnostics and Life Sciences,
PerkinElmer. “With these new live cell imaging capabilities, our customers
will have easy access to a wider range of applications than ever before and
will be able to generate more biologically relevant data on how cells respond
to compounds, helping to reduce false positives later in the drug discovery
process.”

The Operetta system’s new capabilities include brightfield imaging and
environmental chamber options, and a new transmitted light digital
phase-contrast mode that enables users to image and segment live cells without
using fluorescent dyes. This feature reduces toxic effects of nuclear stains
that may negatively impact the viability of cells, enabling longer and more
predictive live cell studies. Furthermore, it can help to reduce assay costs.

In addition to the live cell imaging capabilities, the upgraded Operetta
system is integrated with advanced informatics solutions, such as
PerkinElmer’s Columbus™ Image Data Storage and Analysis System for high
content imaging data, and the TIBCO^® Spotfire^® software for data analysis
and visualization which enables users to easily combine findings across
experiments.

Visit www.perkinelmer.com/Operetta for more information

About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The Company reported revenue of
approximately $2.1 billion in 2012, has about 7,500 employees serving
customers in more than 150 countries, and is a component of the S&P 500 Index.
Additional information is available through 1-877-PKI-NYSE, or at
www.perkinelmer.com.

TIBCO and Spotfire are registered trademarks of TIBCO Software Inc.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130724005135/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50676010&lang=en

Contact:

Edelman (On behalf of PerkinElmer, Inc.)
Paul Barren, 404-460-9679
paul.barren@edelman.com